Keyphrases
Abscopal Response
9%
Anti-tumor Response
9%
Antitumor
9%
Bladder
18%
Bladder Cancer
27%
Bladder Tumor
9%
Cancer Patients
6%
Canine
100%
Canine Bladder Cancer
9%
Checkpoint Immunotherapy
9%
Checkpoint Inhibitors
9%
Chitosan
81%
Chitosan Biopolymer
9%
Clinical Examination Test
9%
Clinical Laboratory Test
9%
Clinical Translation
6%
Dose-escalation Study
9%
Faithful Representation
9%
Human Trials
6%
Immune Response
6%
Immunological Response
6%
Immunophenotyping
6%
Immunotherapy Response
9%
Interleukin-12 (IL-12)
66%
Intravesical
36%
Intravesical Immunotherapy
100%
Invasive Bladder Cancer
9%
Invasive Urothelial Carcinoma
100%
Lethal Infection
9%
Metastasis
6%
Metastasis Sites
9%
Molecular Subtypes
9%
Mucoadhesive
9%
Neoantigen
9%
Novel Immunotherapy
9%
Patient Benefit
6%
Pet Dogs
9%
Recombinant
6%
Recommended Dose
18%
Rodent Models
6%
Specific Intent
6%
Surgical Removal
9%
Systemic Uptake
9%
T Cell Infiltration
9%
T-cell Clonality
9%
T-cell Mediated
9%
Tumor Immune Microenvironment
9%
Tumor Immunity
6%
Tumor mutational Burden
9%
Tumorigenesis Mechanism
9%
Urinary Bladder
9%
Medicine and Dentistry
Biopolymer
6%
Bladder
40%
Bladder Cancer
20%
Bladder Tumor
10%
Carcinogenesis
6%
Cellular Infiltration
10%
Chitosan
100%
Clinical Examination
6%
Clinical Trial
6%
Clonal Variation
10%
Disease
6%
Immune Response
6%
Immunophenotyping
6%
Immunotherapy
66%
In Vitro
6%
Interleukin 12
50%
Invasive Bladder Cancer
10%
Laboratory Test
10%
Malignant Neoplasm
13%
Metastatic Carcinoma
13%
Neoplasm
6%
Recommended Drug Dose
20%
T Cell
20%
Transitional Cell Carcinoma
100%
Tumor Immune Microenvironment
10%
Pharmacology, Toxicology and Pharmaceutical Science
Biopolymer
6%
Bladder Cancer
30%
Bladder Tumor
10%
Carcinogenesis
6%
Chitosan
100%
Clinical Trial
6%
Disease
6%
Elimination
6%
Immunotherapy
66%
Interleukin 12
50%
Malignant Neoplasm
13%
Mouse
13%
Neoplasm
13%
Pet Animal
10%
Preclinical Study
6%
Transitional Cell Carcinoma
100%